| Literature DB >> 25477996 |
Huanqin Li1, Huilin Liu1, Cunzhi Liu1, Guangxia Shi1, Wei Zhou2, Chengmei Zhao3, Tao Zhang1, Xuefei Wang1, Guiling Wang1, Yin Zhao1, Jingqing Sun1, Jing Wang1, Linpeng Wang1.
Abstract
Background. Acupuncture has been shown to reduce spasticity and prevent the onset of spasticity after stroke. The purpose of this study is to assess the effect of "Deqi" during needling "Wang's Jiaji" acupoints treating spasticity in the early stage of stroke. Methods. This study is a multicenter, prospective, randomized, controlled trial. 238 patients with stroke (<21 days) participated and were randomly allocated to the verum-acupuncture (n = 121) group or sham-acupuncture group (n = 117). The verum-acupuncture group received verum acupuncture required to produce the sense of "Deqi" while the sham-acupuncture group received sham acupuncture without "Deqi." Patients in both groups followed the same 30 min acupuncture regimen 5 times per week for a period of 4 weeks. Scales of MAS, FMA, ADL, MBI, NIHSS, SS-QOL, and MRS were measured at baseline and at 2, 4, and 12 weeks after intervention. Results. Significant differences were observed between two groups. The MRS rating composition has the statistical difference after 4 weeks (P = 0.017). The score of MAS, FMA, Barthel, and SSQOL in verum-acupuncture group has increased significantly compared with the sham-acupuncture group after 12 weeks. There was 14% reduction of higher muscle tension in the verum-acupuncture group. Conclusion. Acupuncture "Wang's Jiaji" points with sensation of "Deqi" in the early stage may reduce the occurrence and decrease the severity of spasticity after stroke.Entities:
Year: 2014 PMID: 25477996 PMCID: PMC4247953 DOI: 10.1155/2014/715351
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Figure 1Technology roadmap.
Contrast of gender between treatment group and control group before treatment.
|
Treatment group ( |
Control group ( | Chi-square value |
| |||
|---|---|---|---|---|---|---|
|
| % |
| % | |||
| Gender | ||||||
| Male | 78 | 64.50% | 81 | 69.2% | ||
| Female | 43 | 35.50% | 36 | 30.8% | 0.61 | 0.435 |
Contrast of age between treatment group and control group before treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| Age (Y) | 63.2 | 10.485 | 64.21 | 10.193 | −0.751 | 0.454 |
Contrast of time onset of stroke between treatment group and control group before treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| Time onset (day) | 10.93 | 6.973 | 12.19 | 7.452 | 1.412 | 0.158 |
Contrast of the rate of MRS before treatment.
| Rate of MRS | Chi-square value |
| ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |||
| Treatment group | 0 | 1 | 1 | 24 | 81 | 14 | 6.637 | 0.183 |
| Control group | 2 | 0 | 2 | 35 | 66 | 2 | ||
The scores of MAS, FMA, Barthel, NIHSS, and SSQOL between treatment group and control group before treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 12.47 | 7.468 | 13.01 | 6.137 | −0.605 | 0.545 |
| FMA | 30.32 | 21.573 | 31.52 | 18.962 | −0.455 | 0.650 |
| Barthel | 33.72 | 15.699 | 36.98 | 16.125 | −1.582 | 0.115 |
| NIHSS | 11.13 | 4.649 | 10.62 | 4.386 | 0.882 | 0.379 |
| SSQOL | 102.74 | 31.147 | 106.09 | 35.762 | −0.769 | 0.442 |
Contrast of the rate of MRS after 2 weeks of treatment.
| Rate of MRS | Chi-square value |
| ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |||
| Treatment group | 0 | 10 | 10 | 26 | 68 | 7 | 6.215 | 0.250 |
| Control group | 0 | 14 | 17 | 29 | 49 | 8 | ||
Contrast of MRS rating between treatment group and control group after 4 weeks of treatment.
| MRS rating | Chi-square value |
| ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |||
| Treatment group | 0 | 18 | 30 | 44 | 27 | 2 | 11.437 | 0.017 |
| Control group | 0 | 14 | 27 | 33 | 41 | 2 | ||
Contrast of MRS rating between treatment group and control group after 12 weeks of treatment.
| MRS rating | Chi-square value |
| ||||||
|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | 5 | |||
| Treatment group | 2 | 23 | 44 | 39 | 11 | 2 | 7.621 | 0.151 |
| Control group | 0 | 25 | 28 | 43 | 19 | 2 | ||
The scores of MAS, FMA, Barthel, NIHSS, and SSQOL between treatment group and control group after 2 weeks of treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 18.05 | 10.463 | 17.73 | 9.014 | 0.255 | 0.799 |
| FMA | 45.80 | 25.439 | 44.31 | 18.062 | 0.565 | 0.573 |
| Barthel | 47.44 | 21.116 | 47.03 | 18.824 | 0.158 | 0.874 |
| NIHSS | 9.01 | 7.808 | 9.21 | 8.630 | −0.530 | 0.597 |
| SSQOL | 128.19 | 38.191 | 123.65 | 35.605 | 0.948 | 0.344 |
The scores of MAS, FMA, Barthel, NIHSS, and SSQOL between treatment group and control group after 4 weeks of treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 23.98 | 10.835 | 21.78 | 9.461 | 1.664 | 0.097 |
| FMA | 56.45 | 24.05 | 51.95 | 21.783 | 1.450 | 0.148 |
| Barthel | 55.42 | 21.70 | 55.21 | 20.797 | 1.525 | 0.129 |
| NIHSS | 6.78 | 3.203 | 7.34 | 3.138 | −1.374 | 0.171 |
| SSQOL | 145.29 | 32.978 | 136.60 | 42.97 | 1.771 | 0.078 |
The scores of MAS, FMA, Barthel, NIHSS, and SSQOL between treatment group and control group after 12 weeks of treatment.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 30.78 | 9.448 | 25.91 | 10.525 | 3.753 | 0.000 |
| FMA | 67.90 | 21.695 | 56.42 | 23.825 | 3.89 | 0.000 |
| Barthel | 71.61 | 21.911 | 61.62 | 21.059 | 3.583 | 0.000 |
| NIHSS | 5.36 | 3.284 | 5.62 | 3.365 | −0.604 | 0.546 |
| SSQOL | 169.96 | 38.694 | 146.72 | 44.565 | 4.30 | 0.000 |
The change in value of scores of MAS, FMA, Barthel, NIHSS, and SSQOL between two groups after 2 weeks of treatment compared to the baseline.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | mean | SD | |||
| MAS_ | 5.579 | 9.291 | 4.718 | 6.438 | 0.828 | 0.409 |
| FMA | 15.479 | 20.408 | 12.786 | 12.432 | 1.224 | 0.222 |
| Barthel | 13.719 | 17.566 | 10.026 | 12.314 | 1.867 | 0.063 |
| NIHSS | −2.066 | −4.487 | 1.915 | 4.228 | −0.268 | 0.789 |
| SSQOL | 25.446 | 37.96 | 18.552 | 15.760 | 2.178 | 0.07 |
The change in value of scores of MAS, FMA, Barthel, NIHSS, and SSQOL between two groups after 4 weeks of treatment compared to the baseline.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 11.504 | 10.453 | 8.769 | 7.824 | 2.279 | 0.024 |
| FMA | 26.132 | 23.718 | 20.615 | 14.582 | 2.153 | 0.032 |
| Barthel | 25.703 | 20.609 | 18.231 | 17.710 | 2.995 | 0.003 |
| NIHSS | −4.298 | 4.79 | −3.778 | 4.159 | −0.893 | 0.373 |
| SSQOL | 42.546 | 37.306 | 30.513 | 28.439 | 2.791 | 0.006 |
The change in value of scores of MAS, FMA, Barthel, NIHSS, and SSQOL between two groups after 12 weeks of treatment compared to the baseline.
| Treatment group | Control group |
|
| |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | |||
| MAS_ | 18.306 | 9.073 | 12.906 | 9.876 | 4.395 | 0.000 |
| FMA | 37.759 | 22.376 | 24.897 | 19.737 | 4.631 | 0.000 |
| Barthel | 37.893 | 20.522 | 24.641 | 18.761 | 5.194 | 0.000 |
| NIHSS | −5.711 | 5.021 | −5.496 | 4.408 | −0.351 | 0.726 |
| SSQOL | 67.215 | 39.603 | 40.632 | 33.334 | 5.593 | 0.000 |
The distribution of higher muscle tension patients (Ashworth scores ≥3) in the treatment group and control group after 4 weeks of treatment.
| Ashworth score | Chi-square value |
| ||
|---|---|---|---|---|
| ≥3 | <3 | |||
| Treatment group | 37 | 84 | 5.481 | 0.019 |
| Control group | 53 | 64 | ||
The distribution of higher muscle tension patients (Ashworth scores ≥3) in the treatment group and control group after 4 weeks of treatment.
| Ashworth score | Chi-square value |
| ||
|---|---|---|---|---|
| ≥3 | <3 | |||
| Treatment group | 28 | 93 | 5.90 | 0.015 |
| Control group | 44 | 73 | ||